Evaluation of Prevent ID and Quantum Blue rapid tests for fecal calprotectin

Hessels, Jan; Douw, Geke; Yildirim, Duygu D.; Meerman, Gerrit; Herwaarden, Margot A. van; Bergh, Frank A.J.T.M. van den

doi:10.1515/cclm-2011-0855

Cited by 19 publications

(21 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These in turn imply sensitivities and specificities. In the main these correspond with those of Hessells et al, 98 although there is some very minor disagreement of the order of 1% for a few of the percentages. l vary the prevalence of IBD within the presenting patient population from the base case 48% to 40% and 60% l vary the time to re-presentation among false negatives from the base case 12 weeks to 8 weeks and 16 weeks l change the source of utility estimates from Stark et al 124 and CG61 35 to Gregor et al, 133 Poole et al…”

Section: Primary Care Modelling: Other Estimates Of Test Characteristicssupporting

confidence: 86%

“…Hessells et al 98 compared two rapid tests, Quantum Blue and PreventID CalDetect, using the laboratory quantitative time-resolved fluorimetric immunoassay (TRFIA) as the gold standard, using a cut-off of 50 µg/g ( Table 31). The PreventID is a rapid semiquantitative test, with lines: negative, < 15 µg/g, has two lines; positive, > 60 µg/g, has four lines, and indeterminate, 15-60 µg/g, has three lines.…”

Section: Hessells 2012mentioning

confidence: 99%

“…Additional effectiveness estimates for further analyses are drawn from Otten et al 73 (Table 47) for CalDetect at the 60 µg/g cut-off; from Hessells et al 98 for CalDetect at the 15 and 60 µg/g cut-offs, and for Quantum Blue at the 30, 40, 50 and 60 µg/g cut-offs (Table 48); and, from Basumani et al 83 for ELISA at the 50, 100 and 150 µg/g cut-offs ( Table 49). The central estimates from Otten et al 73 are shown in Table 47.…”

Section: Primary Care Modelling: Other Estimates Of Test Characteristicsmentioning

confidence: 99%

“…In order to characterise the sensitivities and specificities of Hessells et al 98 for the probabilistic modelling, the numbers of true positives, false negatives, true negatives and false positives has to be calculated. Unfortunately, Hessells et al 98 only report the overall sample size, the numbers of correct diagnoses and the sensitivities and specificities.…”

Section: Primary Care Modelling: Other Estimates Of Test Characteristicsmentioning

confidence: 99%

“…Unfortunately, Hessells et al 98 only report the overall sample size, the numbers of correct diagnoses and the sensitivities and specificities. Given this, on the basis of a sample size of 85 the EAG has calculated the number with IBD to be 23, which implies the following numbers of true positives, false negatives, true negatives and false positives.…”

Section: Primary Care Modelling: Other Estimates Of Test Characteristicsmentioning

confidence: 99%

See 4 more Smart Citations

Faecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel diseases: systematic review and economic evaluation

Waugh

Cummins²,

Royle³

et al. 2013

Health Technology Assessment

234

201

View full text Add to dashboard Cite

Section: Primary Care Modelling: Other Estimates Of Test Characteristicssupporting

confidence: 86%

Section: Hessells 2012mentioning

confidence: 99%

Section: Primary Care Modelling: Other Estimates Of Test Characteristicsmentioning

confidence: 99%

Section: Primary Care Modelling: Other Estimates Of Test Characteristicsmentioning

confidence: 99%

Section: Primary Care Modelling: Other Estimates Of Test Characteristicsmentioning

confidence: 99%

See 3 more Smart Citations

Faecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel diseases: systematic review and economic evaluation

Waugh

Cummins²,

Royle³

et al. 2013

Health Technology Assessment

234

201

View full text Add to dashboard Cite

Measuring attack on self: The need for field‐friendly methods development and research on autoimmunity in human biology

Cepon-Robins

2020

American J Hum Biol

View full text Add to dashboard Cite

Background: Autoimmune and inflammatory disorder (AIID) prevalence appears to be increasing in all but the world's poorest regions and countries. Autoimmune diseases occur when there is a breakdown in processes that regulate inflammation and self-recognition by immune cells. Very few field-based studies have been conducted among Indigenous populations and underserved communities with limited access to medical care. This is due, in part, to the fact that autoimmune diseases are difficult to diagnose, even in clinical settings. In remote field settings these difficulties are compounded by the absence of infrastructure necessary for sample storage and analysis, and the lack of hospital/clinic access for more invasive diagnostic procedures. Because of these limitations, little is known about the prevalence of autoimmunity outside wealthy regions and clinical settings. Aims: The present paper discusses why AIID are of critical importance in human biology research and why more work needs to be devoted to validating, testing, and utilizing methods for detecting autoantibodies and other biomarkers related to autoimmunity in field-friendly, minimally invasivelycollected samples. This paper reviews some of the methods used to diagnose AIIDs in clinical settings, and highlights methods that have been used in studies within human biology and related fields, emphasizing the invasiveness of specific methods and their feasibility in remote field settings. Discussion and Conclusions: Risk for AIID is affected by several reproductive, dietary, environmental, and genetic factors. Human biologists have unique perspectives that they can bring to autoimmunity research, and more populationbased studies on autoimmunity are needed within these and related fields.

show abstract

Evaluation of a fluorescent immunochromatography test for fecal calprotectin

Zhao

Dong

et al. 2019

Clinical Laboratory Analysis

View full text Add to dashboard Cite

Background Fecal calprotectin (FC) is widely used to discriminate between patients with inflammatory diseases such as inflammatory bowel disease (IBD) and functional diseases such as irritable bowel syndrome (IBS). ELISA is a time‐consuming method for the measurement of FC, whereas a fluorescent immunochromatography test can obtain results in around 30 minutes and thus enables a rapid response to clinical decision. Methods Two methods, the Proglead® calprotectin (FC Proglead) and the BÜHLMANN fCAL® ELISA (FC BÜHLMANN), were used to quantitatively examine FC in 111 stool samples. The comparison and bias estimation of both assays were assessed using CLSI EP09c protocol. Results The two methods were highly correlated (rho = .96). Deming regression was employed to calculate the regression equation, with a slope of 1.01 and an intercept of −4.98 μg/g. The estimated median bias (FC Proglead − FC BÜHLMANN) was −4.19 μg/g with the 95% limits of agreement (−55.59 to 47.21 μg/g), and the estimated median percent bias was −8.71% with the 95% limits of agreement (−50.31% to 32.90%). There was 4.50% (5/111) of values outside the 95% limits of agreement. Percent biases at the FC cutoff values of 50 and 200 μg/g between both methods evaluated by Deming regression were 8.96% and 1.49%, respectively. The biases were all less than the acceptable standard (10%). And, 99.10% of FC results were in agreement between both methods (kappa = .99, P < .001). Conclusions FC Proglead may be used as a suitable alternative to FC BÜHLMANN for the disease activity assessment for patients with IBD, considering its convenience and shorter turnaround time.

show abstract

Evaluation of Prevent ID and Quantum Blue rapid tests for fecal calprotectin

Cited by 19 publications

References 15 publications

Faecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel diseases: systematic review and economic evaluation

Faecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel diseases: systematic review and economic evaluation

Measuring attack on self: The need for field‐friendly methods development and research on autoimmunity in human biology

Evaluation of a fluorescent immunochromatography test for fecal calprotectin

Contact Info

Product

Resources

About